Literature DB >> 21971116

Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation.

Przemyslaw Rutkowski1, Tomasz Sledzinski, Hanna Zielinska, Slawomir Lizakowski, Elzbieta Goyke, Sylwia Szrok-Wojtkiewicz, Julian Swierczynski, Bolesław Rutkowski.   

Abstract

Chemerin is an adipokine associated with metabolic syndrome, systemic inflammation and innate immune system. It has been suggested recently that the decrease in renal function may cause an increase in serum chemerin concentration. In this paper we investigated the effect of kidney transplantation on elevated serum chemerin concentration in dialyzed patients with end stage renal disease (ESRD). Twenty five ESRD patients were tested before and 3months after the kidney transplantation. The control group was comprised of twenty one healthy subjects. Serum chemerin concentrations were measured using commercial ELISA kit, and were related to clinical status, and biomarkers of renal function. We have shown that the kidney transplantation resulted in the decrease of the serum chemerin concentration. Concomitantly, serum creatinine, blood urea nitrogen, phosphate and C-reactive protein concentrations were significantly reduced, while estimated glomerular filtration rate (eGFR), calcium and hemoglobin substantially increased. Univariate regression analysis showed that serum chemerin concentration was positively correlated with serum creatinine and phosphate concentrations and negatively correlated with eGFR. The results presented here indicate that the serum chemerin concentration in patients with ESRD normalizes after the kidney transplantation, and provide additional evidence that serum chemerin concentration is related to renal function.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971116     DOI: 10.1016/j.regpep.2011.09.005

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

Review 1.  Chemerin as an independent predictor of cardiovascular event risk.

Authors:  Sinan İnci; Gökhan Aksan; Pınar Doğan
Journal:  Ther Adv Endocrinol Metab       Date:  2016-02-08       Impact factor: 3.565

2.  CMKLR1 activation ex vivo does not increase proportionally to serum total chemerin in obese humans.

Authors:  Jay Toulany; Sebastian D Parlee; Christopher J Sinal; Kathryn Slayter; Shelly McNeil; Kerry B Goralski
Journal:  Endocr Connect       Date:  2016-11-08       Impact factor: 3.335

3.  Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease.

Authors:  M Carracedo; A Witasp; A R Qureshi; A Laguna-Fernandez; T Brismar; P Stenvinkel; M Bäck
Journal:  J Intern Med       Date:  2019-07-07       Impact factor: 8.989

4.  Chemerin as a Driver of Hypertension: A Consideration.

Authors:  David J Ferland; Adam E Mullick; Stephanie W Watts
Journal:  Am J Hypertens       Date:  2020-11-03       Impact factor: 2.689

5.  Increased serum chemerin level to predict early onset of aortic valve stenosis.

Authors:  Juris Lurins; Dace Lurina; Peteris Tretjakovs; Vitolds Mackevics; Aivars Lejnieks; Venerando Rapisarda; Vincenzo Baylon
Journal:  Biomed Rep       Date:  2017-11-02

6.  Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level.

Authors:  Hamid Nomani; Hamid Khanmohamadian; Asad Vaisi-Raygani; Ebrahim Shakiba; Maryam Tanhapour; Zohreh Rahimi
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

Review 7.  The complex effects of adipokines in the patients with kidney disease.

Authors:  Sahar Vahdat
Journal:  J Res Med Sci       Date:  2018-07-26       Impact factor: 1.852

8.  Renal Chemerin Expression is Induced in Models of Hypertensive Nephropathy and Glomerulonephritis and Correlates with Markers of Inflammation and Fibrosis.

Authors:  Alexander Mocker; Karl F Hilgers; Nada Cordasic; Rainer Wachtveitl; Carlos Menendez-Castro; Joachim Woelfle; Andrea Hartner; Fabian B Fahlbusch
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.